Skip to main content

Table 1 LSD1 inhibitory (IC50, μM) and antiproliferative (15-day treatment EC50, μM) activities for compounds 1–4

From: Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia

 

LSD1 IC50

MLL-rearranged leukemia

Non-MLL leukemia cells

Breast

Prostate

MV4-11

Molm-13

NB4

U937

MCF-7

LNCaP

1

0.0098

0.010

0.096

19.4

18.9

1.6

3.7

2

0.077

0.084

0.32

18.9

34.6

6.6

10.0

3

0.035

0.020

0.18

>50

>50

13.5

29.9

4

5.3

1.4

12

>50

17.5

>50

>50